Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

#2038

Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p<0.0001) between the treatment arms.

Aim(s): Supplemental updated analysis was requested by regulatory authorities for registration purposes. Quality of life (QoL) was analysed with the same new cut-off date (30.07.2016) for time to clinically relevant deterioration (TTD) in health-related QoL (HRQoL).

Materials and methods: Overall survival (OS) and PFS were evaluated using Kaplan Meier Methodology. HRQoL analysis was based on EORTC QLQC-30 and G.I.NET-21 questionnaires, completed at baseline and every 12 weeks thereafter. TTD was defined as the time from randomization to the first QoL deterioration ≥10 points for each patient in the corresponding domain scale.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Jonathan S

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,